

VARIAN MEDICAL SYSTEMS INC  
Form 8-K  
October 03, 2018

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **September 27, 2018**

**VARIAN MEDICAL SYSTEMS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**                                **1-7598**                                **94-2359345**

(I.R.S.

(State or other jurisdiction    (Commission File    Employer

of incorporation)                        Number)                        Identification  
No.)

**3100 Hansen Way, Palo Alto, CA 94304-1030**

(Address of principal executive offices, including zip code)

**(650) 493-4000**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Edgar Filing: VARIAN MEDICAL SYSTEMS INC - Form 8-K

••Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

••Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

••Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

••Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 3, 2018, Varian Medical Systems, Inc. (the “Company”) announced it has appointed Kolleen T. Kennedy, formerly president of Varian Oncology Systems (“VOS”) to a new role as president of the Proton Solutions division and chief growth officer. Chris Toth, formerly president of Global Commercial & Field Operations, will succeed Kennedy as the new president of VOS. Both executives will report directly to Dow Wilson, Varian’s president and chief executive officer and both changes are effective immediately. A copy of the press release is attached as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

99.1 Press release, dated October 3, 2018, announcing appointment of new division presidents.

**SIGNATURE(S)**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Varian Medical Systems, Inc.

By: /s/ John W. Kuo

Name: John W. Kuo

Title: Senior Vice President, General Counsel and  
Corporate Secretary

Dated: October 3, 2018